Which patients are most likely to die from TTS?
UK researchers have determined patterns of symptoms linked to poor outcomes
The risk of death from the rare clotting syndrome associated with AstraZeneca’s COVID-19 vaccine is highest among patients with severely low platelet count and intracranial haemorrhage, UK researchers have found.
And in 50% of those who develop thrombosis with thrombocytopenia syndrome (TTS), the most common thrombotic site at presentation was the cerebral veins, according to analysis of the first 220 cases reported in the UK.
